• Ferrostatins, Lipid Damage, and Ferroptosis

  2026-09-03

  Skouta and colleagues established ferrostatin-1 as a selective inhibitor of ferroptosis that protects cells by suppressing oxidative lipid damage rather than broadly eliminating reactive oxygen species. Across Huntington’s disease, periventricular leukomalacia, and kidney dysfunction models, the study linked lipid peroxidation with cell death and used mechanistic insight to guide the design of improved ferrostatin analogues.

• Nintedanib (BIBF 1120): Mechanism & Research Use

  2026-09-03

  Nintedanib, also known as BIBF 1120, is an orally active triple angiokinase inhibitor that blocks VEGFR, FGFR, and PDGFR signaling. Its nanomolar biochemical potency supports angiogenesis inhibition pathway studies, while ATRX-deficient glioma findings provide a rationale for carefully controlled receptor tyrosine kinase inhibitor research.

• Phosphatase Inhibitor Cocktail 2: Workflow Guide

  2026-09-02

  Learn how to use Phosphatase Inhibitor Cocktail 2 to preserve phosphorylation states in lysates, immunoprecipitations, kinase assays, and tissue workflows. The guide connects practical sample handling with the ACSF3 findings reported in Cell Genomics while emphasizing controls, compatibility, and troubleshooting.

• RepSox and the Next Wave of iPSC Platelet Research

  2026-09-02

  RepSox offers a mechanistically defined way to interrogate ALK5-dependent TGF-β signaling during pluripotency and differentiation research. This article connects its established reprogramming activity with a 2026 hiPSC-derived platelet manufacturing study while clearly separating validated evidence from translational hypotheses.

• MG-132 Workflows for Oxidative Stress Assays

  2026-09-01

  MG-132 (Z-LLL-al) connects proteasome blockade with measurable changes in ROS, mitochondrial injury, apoptosis, and cell-cycle behavior. This guide translates vascular organoid findings into practical assay designs while emphasizing dose selection, solvent control, and interpretation limits.

• Cytochalasin B: From Actin Mechanism to Translation

  2026-09-01

  A translational framework for using Cytochalasin B (NSC 107658) to connect actin mechanism, phenotype-focused assay design, toxicology controls, and strategic cytoskeletal drug discovery.

• Adefovir Workflows for HBV and OAT1 Research

  2026-08-31

  Adefovir (GS-0393) supports two complementary workflows: quantitative HBV polymerase inhibition and OAT1-mediated renal transport profiling. This practical guide covers formulation, assay design, translational interpretation, and troubleshooting while separating antiviral potency from renal safety signals.

• MDL 28170: Selective Calpain Inhibitor

  2026-08-30

  This scenario-driven guide explains how MDL 28170, Calpain and Cathepsin B Inhibitor, Selective (SKU A4412) can improve mechanistic interpretation in viability, apoptosis, neuroprotection, and injury-model workflows. It connects biochemical selectivity with practical formulation, controls, optimization, and vendor-selection decisions.

• Myriocin: From SPT Blockade to Metabolic Rescue

  2026-08-29

  Myriocin is a potent serine palmitoyltransferase inhibitor with applications extending from sphingolipid metabolism research to metabolic disease models. This article translates recent mouse findings into practical assay and experimental-design guidance while defining the limits of cross-domain interpretation.

• CDK9 inhibitor A3294: Protocol and QC Guide

  2026-08-29

  CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for controlled studies of CDK9-dependent transcription elongation, P-TEFb activity, and HIV-1 propagation in MT4 cells. It should not be treated as a pan-CDK reagent, a therapeutic surrogate, or a solution suitable for long-term storage.

• Uridine, Trisodium Salt in RNA Workflow Design

  2026-08-28

  Uridine, Trisodium Salt supports controlled RNA metabolism experiments while helping researchers separate free-nucleoside effects from activated nucleotide chemistry. This guide translates the PRINT safe-harbor insertion study into practical RNA preparation, cell-assay, vascular-response, and troubleshooting workflows without overstating the reagent’s role.

• Telatinib (BAY 57-9352): Mechanism & Research Use

  2026-08-28

  Telatinib, also called BAY 57-9352, is a multitarget small-molecule kinase inhibitor with reported activity against VEGFR2, VEGFR3, c-Kit, and PDGFRα. Its strongest research rationale is pathway-level investigation of angiogenesis, tumor-cell phenotypes, and combination treatment, not a conclusion of clinical efficacy.

• (S)-(+)-Methoprene Workflows for JH Research

  2026-08-27

  Use (S)-(+)-Methoprene as a controlled juvenile hormone analog to separate receptor-driven responses from endogenous hormone biosynthesis. This practical workflow connects Met activation with larval-state maintenance, insect metamorphosis inhibition, vitellogenesis, and miRNA–mRNA mechanism studies.

• AI-10-49 CBFβ-SMMHC Inhibitor Guide

  2026-08-27

  A practical, evidence-based guide to using AI-10-49, a selective leukemia oncoprotein CBFβ-SMMHC inhibitor (SKU A8694), in leukemia viability, proliferation, target-engagement, and chromatin assays. It connects product specifications with inv(16) acute myeloid leukemia research and highlights controls, stock preparation, interpretation, and vendor-selection considerations.

• Bedaquiline: Mapping Energy Vulnerabilities

  2026-08-26

  Bedaquiline is a diarylquinoline antibiotic whose energy-targeting mechanism offers a precise framework for tuberculosis and cancer metabolism research. This article connects bacterial ATP synthase inhibition with host-directed therapy assay design and explains how to interpret mitochondrial effects without overstating translational evidence.

455 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page